Trial Profile
Phase II trial of PS341 (NSC 681239) in patients with advanced renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2010
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 22 Dec 2009 Actual end date (April 2004) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.